Abstract
In bucillamine-treated patients, persistent proteinuria caused by membranous nephropathy (MN) is a major adverse effect affecting the kidneys. We experienced a case of acute interstitial nephritis (AIN) with MN caused by bucillamine. An 81-year-old Japanese woman with a past medical history of rheumatoid arthritis and hypertension presented with a fever, epigastric pain, and nausea of 1 week’s duration. She had commenced bucillamine 4 months earlier. At the time of admission, her baseline creatinine (0.8 mg/dl) had risen to 6.8 mg/dl. A renal biopsy revealed AIN with concomitant MN. Renal function gradually improved after bucillamine administration was stopped. In addition to MN, bucillamine can cause AIN, which requires a renal biopsy for definitive diagnosis. Given the host of pathological findings that tend to develop in patients using bucillamine, patients receiving the drug who present with symptoms of acute kidney injury should undergo a renal biopsy to determine the presence of AIN.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol. 2006;16:85–91.
Tanaka E, Yamanaka H. DMARDs (disease-modifying antirheumatic drugs). Nippon Rinsho. 2013;71:1199–206.
Isozaki T, Kimura M, Ikegaya N, et al. Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature. Clin Investig. 1992;70:1036–42.
Nakano M, Ueno M, Nishi S, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50:154–60.
Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60:804–17.
Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39:706–12.
Manabe S, Banno M, Nakano M, et al. Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis: case report and literature review. Case Rep Nephrol Dial. 2015;5:30–8.
Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993–2011: a case series. Am J Kidney Dis. 2014;64:558–66.
Muriithi AK, Leung N, Valeri AM, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015;87:458–64.
Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77:956–61.
Goicoechea M, Rivera F, López-gómez JM. Increased prevalence of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2013;28:112–5.
Edwards R, Aronson J. Adverse drugs reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.
Brewster UC, Perazella MA. Acute kidney injury following proton pump inhibitor therapy. Kidney Int. 2007;71(6):589–93.
Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381–5.
Koarada S, Nagano Y, Sakemi T, Syouno Y, Watanabe T. A case of acute interstitial nephritis and nonoliguria acute renal failure induced by cimetidine. Nihon Jinzo Gakkai Shi. 1992;34(11):1227–32.
Tan Y, Yu F, Qu Z, et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol. 2011;6(1):93–100.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared that no conflict of interest exists.
About this article
Cite this article
Takamatsu, N., Takizawa, H., Sugawara, H. et al. Acute interstitial nephritis with membranous nephropathy in bucillamine-treated rheumatoid arthritis. CEN Case Rep 5, 103–107 (2016). https://doi.org/10.1007/s13730-015-0204-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-015-0204-z